After surgery , Group 1 ( 22 patients ) , Group 2 ( 17 patients ) and Group 3 ( 20 patients ) received 7.5 mg bevacizumab , 2.5 mg bevacizumab , and Balanced Salt Solution ( BSS ) subconjunctivally , respectively .